The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 28th 2025
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.
Dr Hatim Husain Discusses HER2, Novel Therapy Exploration in Lung Cancer
September 23rd 2022During the Quality Cancer Care Alliance Summer 2022 National Leadership Summit, Hatim Husain, MD, discusses how HER2 exploration in lung cancer differs from that in breast cancer, as well as novel therapies being explored for HER2 and other disease targets.
Watch
Phase 3 Trial Backs First-line Use of Cemiplimab With Chemotherapy in aNSCLC
September 21st 2022With these new findings coming from the EMPOWER-Lung 3 trial, the anti-programmed cell death-1 inhibitor cemiplimab is now just the second of its kind to show efficacy in these patients as both monotherapy and as a combination regimen, regardless of histology.
Read More
Balancing Hopes for a Cure for SMA, DMD With Realistic Expectations
September 21st 2022A new study looks at the balancing act physicians and families must carry out when managing expectations at a time of great scientific advancement in spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD).
Read More
Stakeholders Address Innovative Strategies Driving Cancer Outcomes in New Jersey
September 20th 2022Key stakeholders involved in the delivery of cancer care in New Jersey discuss strategies driving innovation in oncology and remaining challenges impeding their integration at the 70th Annual Roy A. Bowers Pharmaceutical Conference.
Read More
Review Highlights Advances in SCD Treatment, Potential Targets for Novel Agents
September 17th 2022The review discusses hydroxyurea and 3 additional drugs approved by the FDA—L-glutamine, crizanlizumab, and voxelotor—as well as agents currently being investigated to treat sickle cell disease (SCD).
Read More
ICER Releases Draft Evidence Report on Gene Therapies for Hemophilia A and B
September 17th 2022Despite $2.5 million placeholder price tags, the Institute for Clinical and Economic Review draft evidence report considers gene therapy cost-effective versus comparators in both hemophilia A and B.
Read More
Dr Ajay Nooka Discusses Cost Savings and QOL Benefits of MRD-Directed Treatment Decisions
September 16th 2022Being able to use minimal residual disease (MRD) negativity to make treatment decisions, such as stopping maintenance therapy, can have savings related to cost and quality of life (QOL) for patients, said Ajay Nooka, MD, MPH, FACP, associate professor, Winship Cancer Institute.
Watch
Sustained Glucose Control Does Not Slow Decline of C-Peptide in Randomized T1D Study
September 16th 2022This randomized, multicenter study of children and adolescents with new-onset type 1 diabetes (T1D) investigated the effect on glucose control of a closed-loop system, using C-peptide levels to gauge response
Read More